Reaction
Multiple Use Of Single-Use Product reporting signals
As of the last recalculation, Multiple Use Of Single-Use Product appears in 5,486 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is ONABOTULINUMTOXINA (PRR 292.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Onabotulinumtoxina | 2,857 | 292.0 | 303.2 |
| Testosterone Cypionate | 113 | 49.0 | 49.6 |
| Cyclosporine | 733 | 28.7 | 28.9 |
| Carboxymethylcellulose Sodium | 41 | 16.7 | 16.7 |
| Aflibercept | 117 | 14.5 | 14.6 |
| Insulin Glulisine | 32 | 12.0 | 12.0 |
| Insulin Glargine-Yfgn | 58 | 10.2 | 10.2 |
| Testosterone | 44 | 7.2 | 7.2 |
| Insulin Glargine | 422 | 6.9 | 7.0 |
| Somatropin | 131 | 6.9 | 6.9 |
| Lifitegrast | 23 | 5.4 | 5.4 |
| Insulin Degludec | 25 | 4.1 | 4.1 |
| Moxifloxacin | 15 | 4.0 | 4.1 |
| Moxifloxacin Hydrochloride | 21 | 3.9 | 3.9 |
| Oral Semaglutide | 71 | 3.7 | 3.7 |
| Abaloparatide | 24 | 3.1 | 3.1 |
| Ranibizumab | 19 | 2.7 | 2.7 |
| Insulin Aspart | 43 | 2.5 | 2.5 |
| Interferon Beta-1B | 11 | 2.2 | 2.2 |
| Botulinum Toxin Type A | 7 | 2.1 | 2.1 |
| Bimatoprost | 15 | 2.0 | 2.0 |
| Iohexol | 3 | 1.4 | 1.4 |
| Evolocumab | 39 | 0.9 | 0.9 |
| Levonorgestrel | 37 | 0.7 | 0.7 |